Compass Pathways raised $80M to run the first large psilocybin trial for depression

Compass Pathways is a London-based mental health care company developing psilocybin therapy for treatment-resistant depression, combining the compound with structured psychological support delivered through clinical trials.

Psilocybin, the hallucinogen in magic mushrooms, can become a regulated pharmaceutical therapy for treatment-resistant depression, not stay a fringe substance.

$80M Series B (2020) with participation from ATAI Life Sciences, the McQuade Center for Strategic Research and Development (part of Otsuka), Founders Fund, Able Partners, Camden Partners Nexus, Perceptive Advisors, Skyviews Life Science and Solus Capital, following a £25M (~$31M) Series A in October 2018.

Compass Pathways, founded by George Goldsmith in London, set out to develop psilocybin therapy for treatment-resistant depression through the conventional clinical-trial and FDA pathway, receiving Breakthrough Therapy designation in 2018 and raising a £25M Series A that October.

In April 2020, Compass closed an $80M Series B — its existing investor ATAI Life Sciences returning alongside new backers including Otsuka's McQuade Center, Founders Fund, Able Partners, Camden Partners Nexus, Perceptive Advisors, Skyviews Life Science and Solus Capital. The company said the funds would expand its psilocybin trial program (already running at 20 sites across nine countries), continue research, advance its preclinical pipeline, develop digital technologies, and establish new academic and clinical research partnerships. CEO Goldsmith tied the raise directly to COVID-19's mental-health toll.

FDA Breakthrough Therapy status, won in 2018, made psilocybin development look like conventional drug development to institutional investors.

COVID-19's mental-health toll made a depression pipeline feel urgent to funders in April 2020, per CEO Goldsmith's own framing of the raise.

A pharma investor (Otsuka's McQuade Center) joining alongside ATAI Life Sciences signaled the round as a life-sciences bet, not a psychedelics-culture one.

A stigmatized compound can become a legitimate pharma bet by running it through the same machinery as any drug candidate — breakthrough status, multi-site trials.